OncoMatch/Clinical Trials/NCT07208149
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Official title: A Phase Ib/IIa, Open-Label, Two-Cohort, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) Who Have Progressed After First-Line or Later-Line Therapy
Is NCT07208149 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies MR001 Bispecific Antibody for for triple-negative breast cancer (tnbc).
Treatment: MR001 Bispecific Antibody for — This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
adequate hematopoietic function based on laboratory tests
Kidney function
adequate organ function based on laboratory tests
Liver function
adequate organ function based on laboratory tests
Adequate organ and hematopoietic function based on the laboratory tests
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07208149 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify